Vyndaqel (tafamidis meglumine) Letter of Medical Necessity
Vyndaqel (tafamidis meglumine 20mg x4 capsules = 80mg daily) and its companion product Vyndamax (tafamidis 61mg free acid, once daily) are the first FDA-approved therapies for ATTR-CM. At ~$225,000/year, prior authorization is universal and stringent. Diagnosis must be confirmed by nuclear scintigraphy or biopsy, and AL amyloidosis must be excluded before approval is granted.
FDA-Approved Indications
- ● transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) — wild-type or hereditary — to reduce cardiovascular mortality and cardiovascular-related hospitalization
Why Vyndaqel Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. ATTR-CM diagnosis not confirmed by technetium scintigraphy (99mTc-PYP, DPD, or HMDP scan grade 2–3) or endomyocardial biopsy
- 2. Wild-type vs hereditary variant not specified (TTR gene testing required for hereditary)
- 3. Cardiac imaging (echo or MRI) not provided showing cardiomyopathy pattern
- 4. Etiologies of amyloid cardiomyopathy not excluded (AL amyloid must be ruled out by serum/urine protein electrophoresis and free light chains)
- 5. NYHA functional class not documented
- 6. Vyndamax (tafamidis free acid 61mg) preferred on formulary over Vyndaqel (80mg 4-cap formulation)
What to Include in a Vyndaqel Letter of Medical Necessity
Document ATTR-CM diagnosis confirmed by: (1) technetium pyrophosphate (99mTc-PYP) scintigraphy with grade 2–3 cardiac uptake or endomyocardial biopsy showing amyloid + TTR staining, AND (2) negative serum/urine protein electrophoresis + serum free light chains to exclude AL amyloidosis. Specify wild-type (no TTR mutation) or hereditary variant (include TTR genotyping result). Document cardiac manifestations (echo: interventricular septal thickness ≥12mm, diastolic dysfunction; NT-proBNP elevation), NYHA Class I–III, and absence of contraindications. For Vyndaqel vs Vyndamax — document which formulation is being requested and the clinical rationale if requesting the non-preferred agent.
Key clinical evidence to cite:
- ✓ ATTR-ACT Phase 3 trial — 30% relative risk reduction in all-cause mortality and 32% reduction in CV hospitalizations vs placebo at 30 months
- ✓ First disease-modifying therapy approved for ATTR-CM (wild-type and hereditary)
- ✓ Biomarker reductions: NT-proBNP and 6-minute walk test improvements sustained through extension studies
Relevant guidelines:
- 📖 AHA/ACC 2022 Heart Failure Guidelines (Class IIb for ATTR-CM)
- 📖 European Society of Cardiology 2021 Cardiomyopathy Guidelines
- 📖 Heart Failure Society of America ATTR-CM Expert Consensus
Vyndaqel Prior Authorization Criteria
Standard criteria across major US payers for Vyndaqel. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Vyndaqel
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Vyndaqel Prior Authorization FAQ
Why was my Vyndaqel prior authorization denied?
The most common denial reasons for Vyndaqel are: ATTR-CM diagnosis not confirmed by technetium scintigraphy (99mTc-PYP, DPD, or HMDP scan grade 2–3) or endomyocardial biopsy; Wild-type vs hereditary variant not specified (TTR gene testing required for hereditary); Cardiac imaging (echo or MRI) not provided showing cardiomyopathy pattern; Etiologies of amyloid cardiomyopathy not excluded (AL amyloid must be ruled out by serum/urine protein electrophoresis and free light chains); NYHA functional class not documented; Vyndamax (tafamidis free acid 61mg) preferred on formulary over Vyndaqel (80mg 4-cap formulation).
What should a Vyndaqel Letter of Medical Necessity include?
Document ATTR-CM diagnosis confirmed by: (1) technetium pyrophosphate (99mTc-PYP) scintigraphy with grade 2–3 cardiac uptake or endomyocardial biopsy showing amyloid + TTR staining, AND (2) negative serum/urine protein electrophoresis + serum free light chains to exclude AL amyloidosis. Specify wild-type (no TTR mutation) or hereditary variant (include TTR genotyping result). Document cardiac manifestations (echo: interventricular septal thickness ≥12mm, diastolic dysfunction; NT-proBNP elevation), NYHA Class I–III, and absence of contraindications. For Vyndaqel vs Vyndamax — document which formulation is being requested and the clinical rationale if requesting the non-preferred agent.
Which payers cover Vyndaqel?
Vyndaqel is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.